| Literature DB >> 32411290 |
Lu Huang1,2, Zhuang Peng1,3, Cong Lu4, Ying Chen5, Jing-Wei Lv4, Meng Qin3, Duan-Fang Liao1, Xin-Min Liu1,4, Zhe Shi1.
Abstract
BACKGROUND: Chronic alcohol consumption disrupts psychomotor and cognitive functions, most of which are subserved by the dysfunction of hippocampus. Dysregulated excitatory glutamatergic transmission is implicated in repeated alcohol induced psychomotor and cognitive impairment. Ginsenoside Rg1, one of the main active ingredient of the traditional tonic medicine Panax ginseng C.A. Meyer (Araliaceae), has been used to treat cognitive deficits. Particularly, Rg1 has been demonstrated to improve hippocampus-dependent learning in mice and attenuate glutamate-induced excitotoxicity in vitro. Thus, in the present research, we sought to investigate the therapeutic effects of Ginsenoside Rg1 on repeated alcohol induced psychomotor and cognitive deficits in hippocampal-dependent behavioral tasks and unravel the underpinnings of its neuroprotection.Entities:
Keywords: Excitatory glutamatergic transmission; Ginsenoside Rg1; NR2B containing NMDARs; Psychomotor and cognitive deficits; Repeated alcohol exposure
Year: 2020 PMID: 32411290 PMCID: PMC7206760 DOI: 10.1186/s13020-020-00325-x
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1Ginsenoside Rg1 treatment alleviated repeated alcohol-induced cognitive deficits. a A schematic illustration of the experimental manipulation. b chemical structure of ginsenoside Rg1. c The open field test showed that Rg1 pretreatment decreased RAE-induced psychomotor response. d The object location recognition test demonstrated that the impaired recognition ability was recovered after Rg1 treatment. e–g Mice received Rg1 pretreatment showed better spatial navigation and orientation abilities in the reference learning and memory retention tasks. (*P < 0.05, **P < 0.01, ***P < 0.001, compared with alcohol group; n = 8 per group)
Fig. 2Ginsenoside Rg1 treatment prevented chronic alcohol-induced pathological alteration of neurons in the hippocampus. HE staining of hippocampal neurons in the CA1 (a), CA3 (b) and DG (c) subregions are shown (n = 5 per group, scale bar = 50 μm)
Fig. 3Ginsenoside Rg1 treatment reduced glutamate spillover and NR2B-containing NMDARs activation in the hippocampus. a Alterations in glutamate content. Expression level changes in NR1 (b) and NR2B (c) in the hippocampus (*P < 0.05, **P < 0.01, ***P < 0.001, compared with alcohol group; n = 4 per group in glutamate content examination and n = 3 per group in western blot assay)
Fig. 4Ginsenoside Rg1 exerts neuroprotective effects via suppressing extrasynaptic NMDARs-mediated excitotoxic signaling. Expression level changes in calpain-2 (a), STEP61 (b), STEP33 (c) and p-p38 MAPK (d) in hippocampus are shown (*P < 0.05, **P < 0.01, ***P < 0.001, compared with alcohol group; n = 3 per group)
Fig. 5A schematic diagram illustrating the proposed mechanism by which ginsenoside Rg1 alleviated repeated alcohol-induced cognitive deficits. Repeated alcohol exposure results in glutamate spillover and over-activation of extrasynaptic NR2B-containing NMDARs in the hippocampus. Activated extrasynaptic NMDARs initiates calpain-2/STEP/p38 excitotoxic cascade and leads to pathological changes of neurons in the hippocampus. Rg1 pretreatment can effectively ameliorate cognitive deficits via suppressing extrasynaptic NMDARs-mediated excitotoxic assaults